EBQ:PEITHO Trial: Difference between revisions
Ostermayer (talk | contribs) No edit summary |
Ostermayer (talk | contribs) |
||
| Line 18: | Line 18: | ||
==Conclusion== | ==Conclusion== | ||
*'''Fibrinolytic therapy prevented hemodynamic compensation but at the risk of increased hemorrhage and stroke''' | |||
==Major Points== | ==Major Points== | ||
Revision as of 19:54, 7 September 2014
incomplete Journal Club Article
Meyer G. et al.. "Fibrinolysis for patients with intermediate-risk pulmonary embolism". NEJM. 2014. 10(370):1402-1411.
PubMed Full text PDF
PubMed Full text PDF
Clinical Question
Does thrombolysis with tenecteplase reduce mortality or hemodynamic collapse in patients with sub-massive PE at 7 days compared to placebo?
Conclusion
- Fibrinolytic therapy prevented hemodynamic compensation but at the risk of increased hemorrhage and stroke